Table 1.

Base-case estimates and ranges

Result or transitionEstimateRangeReferences
TITAN    
 Cohort age at start, mean, y 42 19-72 11 
 Probability of death, SOC arm 0.054  11 
 Probability of death, caplacizumab arm 0  11 
 Probability of total recurrence SOC arm 0.324  11 
 Probability of total recurrence, caplacizumab arm 0.314  11 
 Probability of total relapse at 5 y 0.4 0.19-0.4 3, 8, 22 
 Discount rate 0.03 0.015-0.06 23 
HERCULES    
 Cohort age at start, mean, y 46 18-79 12 
 Probability of death, SOC arm 0.041  12 
 Probability of death caplacizumab arm 0.014  12 
 Probability of total recurrence, SOC arm 0.384  12 
 Probability of total recurrence, caplacizumab arm 0.125  12 
 Discount rate 0.03 0.015-0.06 23 
Result or transitionEstimateRangeReferences
TITAN    
 Cohort age at start, mean, y 42 19-72 11 
 Probability of death, SOC arm 0.054  11 
 Probability of death, caplacizumab arm 0  11 
 Probability of total recurrence SOC arm 0.324  11 
 Probability of total recurrence, caplacizumab arm 0.314  11 
 Probability of total relapse at 5 y 0.4 0.19-0.4 3, 8, 22 
 Discount rate 0.03 0.015-0.06 23 
HERCULES    
 Cohort age at start, mean, y 46 18-79 12 
 Probability of death, SOC arm 0.041  12 
 Probability of death caplacizumab arm 0.014  12 
 Probability of total recurrence, SOC arm 0.384  12 
 Probability of total recurrence, caplacizumab arm 0.125  12 
 Discount rate 0.03 0.015-0.06 23 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal